XIENCE Xpedition/Alpine/Sierra in Routine Clinical Practice
IRIS XPEDITION
Evaluation of Effectiveness and Safety of XIENCE Xpedition/Alpine/Sierra in Routine Clinical Practice; A MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY
1 other identifier
observational
4,000
1 country
26
Brief Summary
The purpose of this study is to evaluate effectiveness and safety of XIENCE Xpedition/Alpine/Sierra in Routine Clinical Practice
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2014
Longer than P75 for all trials
26 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 14, 2014
CompletedFirst Posted
Study publicly available on registry
January 22, 2014
CompletedStudy Start
First participant enrolled
May 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
August 30, 2024
CompletedDecember 29, 2025
December 1, 2025
6.2 years
January 14, 2014
December 22, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Composite event rate
Death, non fatal myocardial infarction, Target Vessel Revascularization
1year
Secondary Outcomes (10)
All death
5year
Cardiac death
5year
Myocardial infarction
5year
Composite event of death or myocardial infarction
5year
Composite event of cardiac death or myocardial infarction
5year
- +5 more secondary outcomes
Study Arms (1)
IRIS-Xpedition/Alpine/Sierra Cohort
XIENCE Xpedition/Alpine/Sierra
Interventions
Eligibility Criteria
patients with XIENCE Xpedition or Alpine or Sierra stent
You may qualify if:
- Age 19 and more
- Intervention with XIENCE Xpedition or Alpine or Sierra everolimus eluting coronary stent
- Agreed with written informed consent form
You may not qualify if:
- Intervention with XIENCE Xpedition or Alpine or Sierra everolimus eluting coronary stent and other drug eluting stent at the same time
- Life expectancy of 1year and under
- Cardiac shock
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Seung-Jung Parklead
- CardioVascular Research Foundation, Koreacollaborator
- Abbottcollaborator
Study Sites (26)
Hallym University Sacred Heart Hospital
Anyang, South Korea
Soon Chun Hyang University Hospital Bucheon
Bucheon-si, South Korea
Soon Chun Hyang University Hospital Cheonan
Cheonan, South Korea
Gangwon National Univ. Hospital
Chuncheon, South Korea
Daegu Catholic University Medical Center
Daegu, South Korea
Keimyung University Dongsan Medical Center
Daegu, South Korea
Yeungnam University Medical Center
Daegu, South Korea
The Catholic University of Korea, Daejeon ST. Mary's Hospital
Daejeon, South Korea
Gangneung Asan Hospital
Gangneung, South Korea
Chonnam National University Hospital
Gwangju, South Korea
Gachon University Gil Hospital
Incheon, South Korea
Inha University Hospital
Incheon, South Korea
ChonBuk National University Hospital
Jeonju, South Korea
Kwangju Christian Hospital
Kwangju, South Korea
Dong-A Medical Center
Pusan, South Korea
Inje University HAEUNDAE Paik Hospital
Pusan, South Korea
Inje University Pusan Paik Hospital
Pusan, South Korea
Pusan National University Hospital
Pusan, South Korea
Asan Medical Center
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Seoul Veterans Hospital
Seoul, South Korea
The Catholic University of Korea Seoul St. Mary's Hospital
Seoul, South Korea
The Catholic University of Korea, Yeouido St. Mary's Hospital
Seoul, South Korea
The Catholic University of Korea Uijeongbu St. Mary's Hospital
Uijeongbu-si, South Korea
Ulsan University Hospital
Ulsan, South Korea
Pusan National University Yangsan Hospital
Yangsan, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 5 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- MD,PhD
Study Record Dates
First Submitted
January 14, 2014
First Posted
January 22, 2014
Study Start
May 1, 2014
Primary Completion
July 1, 2020
Study Completion
August 30, 2024
Last Updated
December 29, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will not share
This is not a publicly funded trial.